Analyst Reco. Vera Therapeutics, Inc.

Equities

VERA

US92337R1014

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-09 pm EDT			5-day change	1st Jan Change
35.06 ^USD	-2.56%		+0.37%	+127.96%

Jul. 01	Vera Therapeutics Appoints David Johnson as Chief Operating Officer	MT
Jul. 01	Vera Therapeutics, Inc. Announces Appointment of David L. Johnson as Chief Operating Officer	CI

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Vera Therapeutics Insider Sold Shares Worth $1,304,435, According to a Recent SEC Filing	May. 17	MT
Wedbush Adjusts Vera Therapeutics' PT to $32 From $34, Keeps Neutral Rating	May. 10	MT
Wedbush Raises Vera Therapeutics' Price Target to $34 From $21 After Model Update, Maintains Neutral rating	Mar. 21	MT
Oppenheimer Raises Vera Therapeutics Price Target to $34 From $26, Maintains Outperform Rating	Jan. 26	MT
Raymond James Upgrades Vera Therapeutics to Strong Buy From Outperform, Raises PT to $37 From $29	Jan. 26	MT
Wedbush Raises Vera Therapeutics' Price Target to $21 From $16, Keeps Neutral Rating	Jan. 26	MT
Oppenheimer Initiates Coverage on Vera Therapeutics With Outperform Rating, $26 Price Target	Jan. 25	MT
Cantor Fitzgerald Starts Vera Therapeutics With Overweight Rating	Jan. 08	MT
Raymond James Initiates Vera Therapeutics at Outperform Rating With $29 Price Target	Dec. 18	MT
Jefferies Upgrades Vera Therapeutics to Buy From Hold, Adjusts Price Target to $26 From $18	Nov. 10	MT
HC Wainwright Adjusts Price Target on Vera Therapeutics to $25 From $10, Maintains Buy Rating	23-09-26	MT
Guggenheim Initiates Vera Therapeutics With Buy Rating, $27 Price Target	23-08-16	MT
Wedbush Lifts Vera Therapeutics' Price Target to $16 From $12, Keeps Neutral Rating	23-08-11	MT
HC Wainwright Adjusts Price Target on Vera Therapeutics to $10 From $11, Keeps Buy Rating	23-05-12	MT
Wedbush Raises Vera Therapeutics' Price Target to $9 From $6, Keeps Neutral Rating	23-05-12	MT
JPMorgan Lowers Price Target on Vera Therapeutics to $22 From $38, Maintains Overweight Rating	23-04-12	MT
HC Wainwright Adjusts Vera Therapeutics' Price Target to $11 From $15, Keeps Buy Rating	23-03-29	MT
Wedbush Lowers Vera Therapeutics' PT to $6 From $8, Updates Estimates to Incorporate February Secondary Offering Proceeds; Keeps Neutral Rating	23-03-29	MT
Jefferies Downgrades Vera Therapeutics to Hold From Buy, Slashes Price Target to $6 From $32	23-01-04	MT
HC Wainwright Adjusts Price Target on Vera Therapeutics to $15 From $36, Maintains Buy Rating	23-01-04	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Vera Therapeutics, Inc.

Equities

VERA

US92337R1014

Analyst Reco.

Filters